The US Food and Drug Administration has approved a new once-daily pill for a hard-to-treat form of advanced breast cancer, after a large trial showed it cut the risk of the disease getting worse or of death by 62 per cent in patients whose tumours carry a specific genetic change.
By The BNN Media
The Best News Network
News Beyond the Borders
Silver Spring, United States — The US Food and Drug Administration (FDA) on Monday, 16 November, approved Wilserdly (giredestrant), an oral drug from Genentech, part of the Roche Group, in combination with everolimus for adults with oestrogen receptor (ER)-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval covers patients whose disease came back during or after hormone-based treatment, or got worse after at least one hormone-based treatment once the cancer had spread.

What the FDA Approved
Wilserdly is a next-generation oral selective oestrogen receptor degrader — known as a SERD — a type of drug designed to block and break down the oestrogen receptor that fuels this kind of breast cancer. It is taken as a 30 mg capsule once a day, with or without food, together with everolimus, until the disease progresses or the side effects become unacceptable.
The approval is narrow and specific, and that is the point. It applies only to adults whose tumours carry a mutation in the ESR1 gene, confirmed by an FDA-authorised test. Alongside the drug approval, the FDA authorised the FoundationOne Liquid CDx blood test as a companion diagnostic to identify those patients.
Genentech says Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard hormone combination therapy in a head-to-head Phase III trial in patients whose cancer had already been treated with a CDK4/6 inhibitor, a common earlier therapy.
For patients whose cancer has learned to resist hormone treatment, this is a new option where few existed.
Why ESR1 Mutations Matter
Most breast cancers of this type — ER-positive and HER2-negative — grow in response to oestrogen, and hormone-blocking drugs are the backbone of treatment. But over time, many tumours find a way around those drugs. One of the main escape routes is a change in the ESR1 gene, which alters the oestrogen receptor so that the cancer can keep growing even when hormone therapy is supposed to be starving it.
According to Roche, up to 40 per cent of patients with this type of advanced breast cancer develop ESR1 mutations. Until now, the main drug that could tackle a mutated receptor was fulvestrant, which has to be given by injection into muscle — a painful, clinic-based treatment. An effective pill that targets the same problem has been a long-standing goal in breast cancer research.
The mutation is, in effect, the tumour changing the lock after doctors have found the key — and Wilserdly is designed to fit the new lock.
The evERA Trial: The Evidence Behind the Decision
The approval rests on the Phase III evERA Breast Cancer trial (NCT05306340), a randomised, open-label, multicentre study in 373 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, including 207 patients whose tumours carried ESR1 mutations. The results were published in The New England Journal of Medicine.
Patients were assigned at random to receive either giredestrant 30 mg once daily or a physician’s choice of standard hormone therapy — exemestane, fulvestrant or tamoxifen. Everyone in the trial also received everolimus 10 mg once daily. The main measure was progression-free survival: how long patients lived before their cancer got worse.
In the patients with ESR1 mutations, the results were striking:
- Risk of progression or death cut by 62%: the hazard ratio was 0.38 (95% confidence interval 0.27–0.54; p<0.0001).
- Median progression-free survival of 10 months with Wilserdly plus everolimus, compared with 5.5 months with standard hormone therapy plus everolimus.
- Tumours shrank in 27% of patients on Wilserdly plus everolimus, against 14% on the standard combination.
The FDA noted, however, that data on overall survival — whether the combination helps people live longer — were still immature at the time of the analysis, so no survival benefit has been shown yet.
A near-doubling of the time before the cancer progressed is a meaningful result in a disease where each next treatment typically buys less time than the last.
How the Treatment Is Given
Wilserdly is a prescription medicine supplied as 30 mg capsules, taken once a day by mouth. That matters more than it sounds: the main existing drug against the mutated receptor, fulvestrant, requires monthly injections into muscle, so a daily pill taken at home is a real change in how patients live with their treatment.
The recommended dose is 30 mg once daily with or without food, in combination with everolimus, until the disease progresses or side effects become unacceptable. Women who have not gone through the menopause, and men, also receive a hormone-suppressing medicine alongside it, as they did in the trial.
Genentech says Wilserdly is expected to be available in the United States in the coming weeks. The company told the news outlet STAT that the list price would be about $270,000 a year, a figure that is likely to draw scrutiny from insurers and patient groups as the drug reaches the market.

Safety: What Patients and Doctors Should Know
No cancer drug is free of side effects, and the FDA’s announcement lists them plainly. The most common adverse reactions, affecting at least one in five patients on Wilserdly plus everolimus, were mouth sores (stomatitis), rash, fatigue, diarrhoea, muscle and bone pain, lung inflammation (pneumonitis) and nausea.
The prescribing information also carries warnings for a slow heart rate (bradycardia) and for harm to an unborn baby, so the drug must not be used during pregnancy. Blood tests in the trial also showed falls in haemoglobin, white blood cells and other measures, which doctors will need to monitor.
The side effects are real, but they are the familiar trade-offs of cancer treatment — and doctors will weigh them against a cancer that has stopped responding to standard hormone therapy.
What Comes Next: The 30 November Decision
The 16 November approval is not the end of the story for Wilserdly. The FDA is also reviewing the drug for use after surgery in people with early-stage breast cancer, with a decision due by 30 November 2026.
That application is based on the Phase III lidERA trial and covers adults with ER-positive, HER2-negative, stage I, II and III breast cancer at intermediate to high risk of the cancer coming back. The application was accepted under the FDA’s Priority Review programme. If it is approved, Genentech says Wilserdly would become the first SERD approved for both early-stage (adjuvant) and advanced ER-positive breast cancer.
The review was conducted under the FDA’s Project Orbis, an initiative that allows cancer drug reviews to run in parallel with regulators in other countries — in this case Health Canada and Israel’s Ministry of Health. The FDA also noted that it approved the advanced-cancer application four weeks ahead of its target date.
A New Option After Hormone Therapy Stops Working
The approval landed in a busy week for the regulator: a day later, the FDA approved Lembaz, the first drug shown to help children with a rare fatal disease live longer. For breast cancer specialists, though, Wilserdly’s approval stands on its own. It is the first time a pill has been shown in a head-to-head Phase III trial to beat standard hormone therapy so clearly in patients whose tumours carry the ESR1 mutation.
For the patients it is aimed at — people whose cancer has already outlasted one or more hormone treatments — the drug offers more time before the disease progresses, in a form they can take at home. Whether it also extends lives is a question the ongoing trial follow-up will have to answer, and the 30 November decision will show whether its use can be extended to earlier-stage disease as well.

By The BNN Media
The Best News Network
News Beyond the Borders
Sources: US Food and Drug Administration (approval announcement, 16 Nov 2026); Genentech / Roche press release via BusinessWire (16 Nov 2026); MedicalXpress (16 Nov 2026); Cancer Therapy Advisor (20 Nov 2026).